SCHEMBL6512804

SCHEMBL6512804

COc1ccc(S(=O)(=O)c2c[nH]c3ccc(Oc4c(Br)cc(CC(=O)O)cc4Br)cc23)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.55
KDM4E B2RXH2 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
THRB P10828 10/20 0.47
THRA P10827 9/20 0.47
MMP2 P08253 3/20 0.44
MMP8 P22894 3/20 0.44
MMP12 P39900 3/20 0.44
MMP13 P45452 3/20 0.44
MMP14 P50281 3/20 0.44
MMP16 P51512 3/20 0.44
MMP9 P14780 2/20 0.44
TP53 P04637 1/20 0.44
MMP1 P03956 1/20 0.42
MMP3 P08254 1/20 0.42
CPT1A P50416 1/20 0.42
CPT1B Q92523 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6516503 0.93 MAPT (0.58) MAPTKDM4ESMN1; SMN2LMNAHTT
SCHEMBL6512816 0.91 THRB (0.50) MAPTTHRBTHRA
SCHEMBL6514008 0.91 SMN1; SMN2 (0.49) MAPTKDM4ESMN1; SMN2LMNAHTT
SCHEMBL6515298 0.91 MAPT (0.55) MAPTKDM4ESMN1; SMN2LMNAHTT
SCHEMBL6522316 0.91 SMN1; SMN2 (0.49) MAPTKDM4ESMN1; SMN2LMNAHTT
SCHEMBL6515541 0.90 MAPT (0.59) MAPTKDM4ESMN1; SMN2LMNAHTT
SCHEMBL6513862 0.89 THRB (0.44) MAPTTHRBTHRA
SCHEMBL6524629 0.89 MAPT (0.55) MAPTKDM4ESMN1; SMN2LMNAHTT
SCHEMBL6515704 0.88 THRB (0.55) MAPTKDM4ESMN1; SMN2LMNAHTT
SCHEMBL6520241 0.88 MAPT (0.56) MAPTKDM4ESMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032874-A1 Anticholesterol agents; arteriosclerosis BAYER AKTIENGESELLSCHAFT (DE) 2005-02-10 US disclosed
US-6794406-B2 FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA BAYER AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
US-20030078288-A1 Indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078288-A1 Indole derivatives IDO1, IDO2, TPH2 MAPT 839/4885KDM4E 1199/4885SMN1; SMN2 4749/4885
US-20050032874-A1 Anticholesterol agents; arteriosclerosis HMGCR, CYP46A1, EBP MAPT 3453/4885KDM4E 2994/4885SMN1; SMN2 4875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.